India Pharma Outlook Team | Tuesday, 01 September 2026
Autoimmune therapies, oncology advances, and major takeovers take center stage as three significant biologics deals reshape industry pipelines today.
Global and regional players move aggressively to secure next-generation assets. Eli Lilly expands its immunology reach, Samsung Biologics launches a full takeover of PolyPeptide Group, and Cipla gains access to a promising HER2-targeted antibody-drug conjugate.
These transactions highlight rising demand for precision biologics that address complex diseases more effectively.
Companies prioritize differentiated assets over traditional approaches. The activity signals a clear shift toward specialized platforms that can deliver meaningful clinical impact across cancer and immune disorders.
Eli Lilly announces its plan to buy privately held Merida Biosciences for up to USD 2.88 billion in cash. The deal supports Lilly’s effort to expand beyond obesity and diabetes into immunity-related conditions. Merida develops medicines that selectively target disease-causing antibodies.
Its lead candidate, MER511, targets Graves’ disease and thyroid eye disease. Early data show MER511 substantially lowers thyroid-stimulating antibodies while maintaining a favorable safety profile.
“We’re building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects,” said Francisco Ramirez-Valle, Senior Vice President, Lilly Immunology Research and Early Clinical Development.
Merida’s pipeline also includes MER769 for food allergy, asthma and other allergic diseases, plus earlier programs for kidney and immune-mediated conditions. Lilly expects the transaction to close in the fourth quarter of 2026. The acquisition adds assets designed to change disease course rather than merely manage symptoms.
Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future
Samsung Biologics confirms it will launch its takeover offer for Swiss contract drugmaker PolyPeptide Group in September. The South Korean company offers 1.46 billion Swiss francs, or about USD 1.80 billion. Shareholders receive 44.31 francs per registered share through unit Samsung Peptide.
The offer period runs from September 15 to October 12. PolyPeptide’s board unanimously recommends its shareholders accept the offer. Samsung aims to delist PolyPeptide from the Swiss stock exchange after completion. The companies first announced the planned all-cash bid in July.
Cipla enters an exclusive licensing and supply agreement with Sino Biopharmaceutical Limited for TQB2102, also known as Rolditamig Deuderuxtecan. This potential best-in-class HER2 bispecific antibody-drug conjugate targets HER2-expressing cancers.
Sino Biopharma subsidiary Chia Tai Tianqing grants Cipla exclusive rights to develop and commercialize the therapy in India, South Africa and five other emerging markets. Cipla handles local clinical development, regulatory filings and commercialization. Chia Tai Tianqing continues to manufacture and supply the product.
“At Cipla, innovation is central to our mission of expanding access to therapies that address unmet patient needs. Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate,” said Achin Gupta, Managing Director and Global Chief Executive Officer.
TQB2102 shows encouraging potential, particularly in patients with HER2-low advanced breast cancer. The partnership combines Sino Biopharma’s oncology pipeline with Cipla’s regulatory expertise and market access strength across emerging regions.
These three deals reveal a coordinated industry push toward high-value biologics assets and consolidation. Lilly deploys capital from its obesity franchise to build an immunology pipeline with disease-modifying potential.
Samsung Biologics moves to fully acquire PolyPeptide Group and take it private. Cipla accelerates access to advanced oncology innovation for patients in high-growth markets.
Together, these transactions underscore how companies now prioritize targeted modalities like autoimmune antibody depletion, HER2 ADCs and strategic takeovers of specialized contract players over broader traditional portfolios.
Cross-border partnerships and acquisitions enable faster pipeline expansion and wider patient reach. Market observers expect this momentum to continue as firms compete for differentiated assets that address significant unmet needs in oncology and immunology.
.jpg)
